Abstract:
At present, multidisciplinary and multifactorial problems that have arisen and are
developing at the intersection of several medical specialties are becoming particularly
complex. One of these tasks is to study the features of diagnosis and treatment of
rheumatic diseases in patients with chronic diffuse liver disease (CDD), especially
chronic viral hepatitis (CHD), HAI and fatty liver (hepatic steatosis - SP). More
precisely, liver damage in rheumatoid arthritis (RA) can be associated with toxic lesions
caused by various drugs, primary (in autoimmune hepatitis - AIH) or secondary (against
the background of diffuse connective tissue diseases), immunological and viral damage.
This, in turn, requires the exclusion of secondary conditions before assessing
pathological conditions in the liver. For early diagnosis of liver damage in RA patients,
it is necessary to conduct regular examinations to assess the functional and organic state
of the liver. In addition, it is very important to correctly and fully collect anamnestic
data, to choose the right methods of clinical and laboratory examination. According to
the literature, the use of determination of microRNA expression as a molecular
diagnostic marker in this category of patients may prove to be highly effective in
addressing these complications. Despite a lot of research, there is still no clear opinion
on the use of treatments for patients with RA and liver disease. If it is possible to clarify
the etiology and pathogenesis of liver damage in RA depending on the expression of
microRNAs or to stratify risk groups for liver damage in RA by these biomarkers, it will
be possible to achieve some progress in the treatment of these comorbid pathologies.
The following literature review comprehensively discusses these problems and their
modern solutions
